Alnylam Pharmaceuticals (ALNY) Research & Development (2009 - 2026)

Alnylam Pharmaceuticals (ALNY) has reported Research & Development for 18 consecutive years, with $413.1 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development rose 27.66% year-over-year to $413.1 million; the trailing twelve-month figure through Jun 2026 stood at $1.5 billion (up 30.11% YoY), and the FY2025 full-year result was $1.3 billion, up 17.19% from the prior year.
• Research & Development improved to $413.1 million in Q2 2026 per ALNY's latest filing, from $364.9 million in the prior quarter.
• Across five years, Research & Development topped out at $413.1 million in Q2 2026 and bottomed at $169.9 million in Q1 2022.
• Historically, Research & Development has averaged $284.0 million across 5 years, with a median of $268.0 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Research & Development decreased 8.61% in 2022, then soared 37.62% in 2026.
• Over 5 years, Research & Development stood at $262.0 million in 2022, then climbed by 3.86% to $272.1 million in 2023, then increased by 10.3% to $300.2 million in 2024, then increased by 24.0% to $372.2 million in 2025, then climbed by 10.99% to $413.1 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $413.1 million, $364.9 million, and $372.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.